GlassScriptPhysician profile
Morgan Magnuson
NPI 1568228989
$11,022.85
in general payments reported to CMS, 2019-2025
31 companies · $6,118 in 2025
The $6,118 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,905 · 2025: $6,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,745.74 |
| Education | $277.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,415.03 | 2024-2025 | |
| Galderma Laboratories, L.P. | $935.41 | 2024-2025 | Nemluvio, Aklief |
| Abbvie INC. | $825.41 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $813.16 | 2024-2025 | |
| Ucb, INC. | $771.98 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $697.62 | 2024-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $689.81 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $664.93 | 2024-2025 | Cabtreo, Siliq, Targretin |
| Dermavant Sciences, INC. | $435.35 | 2024 | Vtama |
| Incyte Corporation | $415.56 | 2024-2025 | Opzelura |
| Amgen INC. | $385.62 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $370.32 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $335.86 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $329.91 | 2024-2025 | Tremfya |
| Kerecis Limited | $285.80 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $254.69 | 2024-2025 | |
| Leo Pharma INC. | $250.17 | 2024-2025 | Adbry, Anzupgo |
| Organon LLC | $231.56 | 2025 | Vtama |
| Almirall LLC | $170.90 | 2024-2025 | Klisyri, Seysara |
| Janssen Scientific Affairs, LLC | $114.99 | 2025 | Tremfya |
| Mayne Pharma Commercial LLC | $98.09 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $93.89 | 2024-2025 | Sotyktu |
| Kyowa Kirin, INC. | $91.60 | 2024 | Poteligeo |
| Biofrontera INC. | $89.19 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Paratek Pharmaceuticals, INC. | $57.06 | 2024-2025 | Nuzyra |
| Botanix Sb INC | $52.45 | 2025 | Sofdra |
| Journey Medical Corporation | $45.35 | 2024-2025 | |
| Genentech USA, INC. | $29.97 | 2025 | Xolair |
| Alvogen INC | $28.56 | 2024 | Teriparatide |
| Springworks Therapeutics, INC. | $23.38 | 2025 | Gomekli |
| Chiesi USA, INC. | $19.23 | 2024 | Filsuvez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Magnuson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.